ArticleRSC advances2026
Controlled aqueous nanoassembly-driven fully automated Fmoc solid-phase peptide synthesis (SPPS) with in-water coupling.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fmoc-based solid-phase peptide synthesis (SPPS) is a cornerstone of modern peptide manufacturing; however, its reliance on dimethylformamide (DMF)-a toxic and environmentally regulated solvent-poses significant sustainability challenges. Herein, we report a controlled aqueous nanoassembly-based strategy that enables fully automated Fmoc-SPPS under water-based coupling conditions. Aqueous nanoassemblies of Fmoc-protected amino acids, generated through a simple two-step preparation protocol, provide a stable and reactive coupling environment compatible with automated synthesis. The methodology was implemented on a commercially available peptide synthesizer and applied to peptides of varying lengths and sequence complexities, affording products of acceptable purity. Importantly, the platform was applied to the automated synthesis of long-chain peptides exceeding 30 residues, including GLP-1 (1-37), demonstrating its applicability to challenging sequences. At the time of writing, this represents, to the best of our knowledge, one of the earliest fully automated Fmoc-SPPS platforms employing water-based coupling cycles without the use of DMF. By eliminating DMF and employing environmentally benign solvents such as water and ethyl acetate, the present methodology provides a practical and sustainable alternative to conventional SPPS, advancing green practices in automated peptide synthesis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.